Fmri, antipsychotics and schizophrenia. influence of different antipsychotics on bold-signal

Current Pharmaceutical Design

Volumn 16, Issue 18, 2010, Pages 2012-2025

  Röder, Christian H ^a   Hoogendam, Janna Marie ^b   van der Veen, Frederik M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotics; Bold; Dopamine receptor; Fmri; Review; Schizophrenia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; HISTAMINE RECEPTOR; MUSCARINIC RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN RECEPTOR; ZIPRASIDONE; OXYGEN;

ANTICIPATION; ARTICLE; ATTENTION; BINDING AFFINITY; BLOOD OXYGEN LEVEL DEPENDENT SIGNAL; DRUG RECEPTOR BINDING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMOTION; FINGER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; OXYGEN BLOOD LEVEL; PREPULSE INHIBITION; PRIORITY JOURNAL; REWARD; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TASK PERFORMANCE; VERBAL MEMORY; WORKING MEMORY; ANIMAL; BLOOD; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ANTIPSYCHOTIC AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; MAGNETIC RESONANCE IMAGING; OXYGEN; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 77953531345     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791293088     Document Type: Article

References (61)

1. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990; 87(24): 9868-72.
2. Liu HL, Pu Y, Nickerson LD, Liu Y, Fox PT, Gao JH. Comparison of the temporal response in perfusion and BOLD-based event-related functional MRI. Magn Reson Med 2000; 43(5): 768-72.
3. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature 2001; 412(6843): 150-7.
4. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988; 1(3): 179-86.
5. Camps M, Cortes R, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience 1989; 28(2): 275-90.
6. De Keyser J, Claeys A, De Backer JP, Ebinger G, Roels F, Vauquelin G. Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett 1988; 91(2): 142-7.
7. Hall H, Halldin C, Jerning E, Osterlund M, Farde L, Sedvall G. Autoradiographic comparison of epidepride and NCQ 298 binding to human brain extrastriated dopamine receptors. Nucl Med Biol 1997; 24(5): 389-93.
8. Iversen LI, Iversen SD, Bloom FE, Roth RH. Introduction to Neuropsychopharmacology. Oxford: Oxford University Press 2009.
9. Choi JK, Chen YI, Hamel E, Jenkins BG. Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage 2006; 30(3): 700-12.
10. Khan ZU, Koulen P, Rubinstein M, Grandy DK, Goldman-Rakic PS. An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proc Natl Acad Sci USA 2001; 98(4): 1964-9.
11. Amenta F, Ricci A, Vega JA. Autoradiographic localization of dopamine receptors in rat cerebral blood vessels. Eur J Pharmacol 1991; 192(1): 123-32.
12. Krimer LS, Muly EC, III, Williams GV, Goldman-Rakic PS. Dopaminergic regulation of cerebral cortical microcirculation. Nat Neurosci 1998; 1(4): 286-9.
13. Goldman RG, Alexander GE, Zemishlany Z, Mukherjee S, Sackeim H, Prohovnik I. Acute effects of haloperidol on cerebral cortex blood flow in normal and schizophrenic subjects. Biol Psychiatry 1996; 40(7): 604-8.
14. Buchsbaum MS, Potkin SG, Siegel BV, Jr, Lohr J, Katz M, Gottschalk LA, et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry 1992; 49(12): 966-74.
15. Tost H, Meyer-Lindenberg A, Klein S, Schmitt A, Hohn F, Tenckhoff A, et al. D2 antidopaminergic modulation of frontal lobe function in healthy human subjects. Biol Psychiatry 2006; 60(11): 1196-205.
16. Brassen S, Tost H, Hoehn F, Weber-Fahr W, Klein S, Braus DF. Haloperidol challenge in healthy male humans: a functional magnetic resonance imaging study. Neurosci Lett 2003; 340(3): 193-6.
17. Abler B, Erk S, Walter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study. Psychopharmacology (Berl) 2007; 191(3): 823-33.
18. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD. Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 2006; 442(7106): 1042-5.
19. Dodds CM, Clark L, Dove A, Regenthal R, Baumann F, Bullmore E, et al. The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Psychopharmacology (Berl) 2009; 207(1): 35-45.
20. Blasi G, Popolizio T, Taurisano P, Caforio G, Romano R, Di GA, et al. Changes in prefrontal and amygdala activity during olanza-pine treatment in schizophrenia. Psychiatry Res 2009; 173(1): 31-8.
21. Schlosser R, Gesierich T, Kaufmann B, Vucurevic G, Hunsche S, Gawehn J, et al. Altered effective connectivity during working memory performance in schizophrenia: a study with fMRI and structural equation modeling. Neuroimage 2003; 19(3): 751-63.
22. Stephan KE, Magnotta VA, White T, Arndt S, Flaum M, O'Leary DS, et al. Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychol Med 2001; 31(6): 1065-78.
23. Braus DF, Ende G, Weber-Fahr W, Sartorius A, Krier A, Hubrich-Ungureanu P, et al. Antipsychotic drug effects on motor activation measured by functional magnetic resonance imaging in schizophrenic patients. Schizophr Res 1999; 39(1): 19-29.
24. Jones HM, Brammer MJ, O'Toole M, Taylor T, Ohlsen RI, Brown RG, et al. Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study. Biol Psychiatry 2004; 56(12): 938-42.
25. Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wustenberg T, Villringer A, et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 2006; 187(2): 222-8.
26. Kirsch P, Ronshausen S, Mier D, Gallhofer B. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. Pharmacopsychiatry 2007; 40(5): 196-8.
27. Kumari V, Antonova E, Geyer MA, Ffytche D, Williams SC, Sharma T. A fMRI investigation of startle gating deficits in schizo-phrenia patients treated with typical or atypical antipsychotics. Int J Neuropsychopharmacol 2006; 1-15.
28. Muller JL, Roder CH, Schuierer G, Klein H. Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26(3): 421-6.
29. Muller JL, Roder C, Schuierer G, Klein HE. Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study. Psychiatry Clin Neurosci 2002; 56(1): 77-84.
30. Surguladze SA, Chu EM, Evans A, Anilkumar AP, Patel MX, Timehin C, et al. The effect of long-acting risperidone on working memory in schizophrenia: a functional magnetic resonance imaging study. J Clin Psychopharmacol 2007; 27(6): 560-70.
31. Fahim C, Stip E, Mancini-Marie A, Gendron A, Mensour B, Beauregard M. Differential hemodynamic brain activity in schizophrenia patients with blunted affect during quetiapine treatment. J Clin Psychopharmacol 2005; 25(4): 367-71.
32. Stip E, Fahim C, Mancini-Marie A, Bentaleb LA, Mensour B, Mendrek A, et al. Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29(1): 21-6.
33. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 1999; 96(23): 13432-7.
34. Keedy SK, Rosen C, Khine T, Rajarethinam R, Janicak PG, Sweeney JA. An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry Res 2009; 172(1): 16-23.
35. Meisenzahl EM, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T, et al. Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. Eur Arch Psychiatry Clin Neurosci 2006; 256(8): 522-31.
36. Schlagenhauf F, Wustenberg T, Schmack K, Dinges M, Wrase J, Koslowski M, et al. Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory. Eur Neuropsychopharmacol 2008; 18(8): 589-99.
37. Schlagenhauf F, Juckel G, Koslowski M, Kahnt T, Knutson B, Dembler T, et al. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) 2008; 196(4): 673-84.
38. Snitz BE, MacDonald A, III, Cohen JD, Cho RY, Becker T, Carter CS. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry 2005; 162(12): 2322-9.
39. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14(2): 87-96.
40. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172(13): 1703-11.
41. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350(6319): 610-4.
42. Burns MJ. The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol 2001; 39(1): 1-14.
43. Baddeley AD, Hitch GJ. In: Bower GA. Ed. The Psychology of Learning and Motivation New York: Academic Press 1974; pp. 47-89.
44. Barch DM. What can research on schizophrenia tell us about the cognitive neuroscience of working memory? Neuroscience 2006; 139(1): 73-84.
45. Breiter HC, Aharon I, Kahneman D, Dale A, Shizgal P. Functional imaging of neural responses to expectancy and experience of monetary gains and losses. Neuron 2001; 30(2): 619-39.
46. Juckel G, Schlagenhauf F, Koslowski M, Wustenberg T, Villringer A, Knutson B, et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006; 29(2): 409-16.
47. Gur RC, Schroeder L, Turner T, McGrath C, Chan RM, Turetsky BI, et al. Brain activation during facial emotion processing. Neuroimage 2002; 16(3 Pt 1): 651-62.
48. Lang PJ, Bradley MM, Cuthbert BN. International Affective Picture System (IAPS): Instruction manual and affective ratings. 2001.
49. Khushu S, Kumaran SS, Tripathi RP, Gupta A, Jain PC, Jain V. Functional magnetic resonance imaging of the primary motor cortex in humans: response to increased functional demands. J Biosci 2001; 26(2): 205-15.
50. Thermenos HW, Goldstein JM, Buka SL, Poldrack RA, Koch JK, Tsuang MT, et al. The effect of working memory performance on functional MRI in schizophrenia. Schizophr Res 2005; 74(2-3): 179-94.
51. Karch S, Leicht G, Giegling I, Lutz J, Kunz J, Buselmeier M, et al. Inefficient neural activity in patients with schizophrenia and nonpsychotic relatives of schizophrenic patients: evidence from a working memory task. J Psychiatr Res 2009; 43(15): 1185-94.
52. Callicott JH, Mattay VS, Bertolino A, Finn K, Coppola R, Frank JA, et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cereb Cortex 1999; 9(1): 20-6.
53. Desimone R. Neuropsychology. Is dopamine a missing link? Nature 1995; 376(6541): 549-50.
54. Riehemann S, Volz HP, Stutzer P, Smesny S, Gaser C, Sauer H. Hypofrontality in neuroleptic-naive schizophrenic patients during the Wisconsin Card Sorting Test a fMRI study. Eur Arch Psychiatry Clin Neurosci 2001; 251(2): 66-71.
55. Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E, et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry 2000; 48(2): 99-109.
56. Callicott JH, Mattay VS, Verchinski BA, Marenco S, Egan MF, Weinberger DR. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 2003; 160(12): 2209-15.
57. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995; 376(6541): 572-5.
58. McGonigle DJ, Howseman AM, Athwal BS, Friston KJ, Frackowiak RS, Holmes AP. Variability in fMRI: an examination of intersession differences. Neuroimage 2000; 11(6 Pt 1): 708-34.
59. Landau SM, Schumacher EH, Garavan H, Druzgal TJ, D'Esposito M. A functional MRI study of the influence of practice on component processes of working memory. Neuroimage 2004; 22(1): 211-21.
60. Sayala S, Sala JB, Courtney SM. Increased neural efficiency with repeated performance of a working memory task is information-type dependent. Cereb Cortex 2006; 16(5): 609-17.
61. Manoach DS, Halpern EF, Kramer TS, Chang Y, Goff DC, Rauch SL, et al. Test-retest reliability of a functional MRI working memory paradigm in normal and schizophrenic subjects. Am J Psychiatry 2001; 158(6): 955-8.